Compare Mesoblast Limited (MESO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Materials Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $14.13 (market cap $1.75B), while Materials Select Sector SPDR Fund trades at $49.54 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 4.4× Mesoblast Limited's market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| MESO | XLB | |
|---|---|---|
Market Cap | $1.75B | $7.73B |
Volume | 239,027 | 13,681,146 |
Sector | Health | — |
52-Week High | $20.96 | $53.67 |
52-Week Low | $13.19 | $42.23 |
Typical Hold Time | 14 Days | 70 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
XLB trades at $49.49, up 1.04% with a bearish technical signal from moving averages. The materials ETF shows neutral oscillators but faces selling pressure with ADX indicators signaling strong trends. Recent news highlights sector concentration risks with chemicals comprising 49% of assets, while infrastructure and manufacturing trends provide support. The ETF remains below its 200-day moving average of $50.93, indicating technical weakness.
Outlook remains cautious as materials sector faces cyclical headwinds with limited upside after recent rebound. Investment opportunity exists in AI-resistant businesses and infrastructure exposure, but risks include heavy concentration in chemicals and moderate overvaluation in construction materials. Wall Street sentiment appears mixed with some analysts viewing current levels as fully valued.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
